Mutations of the β - and γ -catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Beta-catenin forms complexes with Tcf and Lef-1 and functions as a transcriptional activator in the Wnt signalling pathway. Although recent investigations have been focused on the role of the adenomatous polyposis coli (APC)/ beta-catenin/Tcf pathway in human tumorigenesis, there have been very few reports on mutations of the beta-catenin gene in a variety of tumour types. Using PCR and single-strand conformational polymorphism analysis, we examined 93 lung, 9 breast, 6 kidney, 19 cervical and 7 ovarian carcinoma cell lines for mutations in exon 3 of the beta-catenin gene. In addition, we tested these same samples for mutations in the NH2-terminal regulatory region of the gamma-catenin gene. Mutational analysis for the entire coding region of beta-catenin cDNA was also undertaken in 20 lung, 9 breast, 5 kidney and 6 cervical carcinoma cell lines. Deletion of most beta-catenin coding exons was confirmed in line NCI-H28 (lung mesothelioma) and a silent mutation at codon 214 in exon 5 was found in HeLa (cervical adenocarcinoma). A missense mutation at codon 19 and a silent mutation at codon 28 in the NH2-terminal regulatory region of the gamma-catenin gene were found in H1726 (squamous cell lung carcinoma) and H1048 (small cell lung carcinoma), respectively. Neither deletions nor mutations of these genes were detected in the other cell lines examined. These results suggest that beta- and gamma-catenins are infrequent mutational targets during development of human lung, breast, kidney, cervical and ovarian carcinomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Functional interaction of β-catenin with the transcription factor LEF-1
Behrens, J., von Kries, J. P., Kühl, M., Bruhn, L., Wedlich, D., Grosschedl, R., & Birchmeier, W. (1996) · Nature · doi:10.1038/382638a0 · Cited by 2,912 · cited 1×
“…adhesion regulator when co with cadherins (Barth et al, 1997) and as a transcriptional regu in the wingless/Wnt signal transduction pathway (Behrens e 1996). β-catenin forms complexes with Tcf and Lef-1 and fun tions to transactivate downstream target genes of the Wnt path (Behrens et al, 1996).”
Background
Cited by
Wnt Signaling Pathway in Non-Small Cell Lung Cancer
Stewart, D. J. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt356 · Cited by 651
Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression
Uematsu, K., He, B., You, L., Xu, Z., McCormick, F., & Jablons, D. M. (2003) · Oncogene · doi:10.1038/sj.onc.1206817 · Cited by 314
WNT Signaling in Lung Disease: A Failure or a Regeneration Signal?
Königshoff, M., & Eickelberg, O. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0485tr · Cited by 258
Targeting the Wnt pathway in human cancers: Therapeutic targeting with a focus on OMP-54F28
Le, P. N., McDermott, J. D., & Jimeno, A. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.005 · Cited by 253
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma
Merle, P., de la Monte, S., Kim, M., Herrmann, M., Tanaka, S., Von Dem Bussche, A., Kew, M. C., Trepo, C., & Wands, J. R. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.009 · Cited by 249
Wnt signalling in lung development and diseases
Pongracz, J. E., & Stockley, R. A. (2006) · Respiratory Research · doi:10.1186/1465-9921-7-15 · Cited by 242
“As β-catenin mutations in lung cancers are relatively rare [79,80,87], another possible mechanism might be at place which regulates EMT and consequently tumour metastasis in the lung.”
Backgroundp53 mutation as a source of aberrant β-catenin accumulation in cancer cells
Cagatay, T., & Ozturk, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205919 · Cited by 110
“…cancers including colorectal, lung, breast, cervix cancers, melanoma, HCC and hepatoblastoma (Candidus et al., 1996; Rimm et al., 1999; Chung, 2000; Johnsson et al., 2000; Lin et al., 2000; Park et al., 2001; Shinohara et al., 2001; Ueda et al., 2001; Hommura et al., 2002; Inagawa et al., 2002).”
BackgroundMethodWnt Signaling in Renal Cell Carcinoma
Xu, Q., Krause, M., Samoylenko, A., & Vainio, S. (2016) · Cancers · doi:10.3390/cancers8060057 · Cited by 99
HPV16 E6 augments Wnt signaling in an E6AP-dependent manner
Lichtig, H., Gilboa, D. A., Jackman, A., Gonen, P., Levav-Cohen, Y., Haupt, Y., & Sherman, L. (2010) · Virology · doi:10.1016/j.virol.2009.10.011 · Cited by 61
Metadata
- Authors
- Ueda, M., Gemmill, R. M., West, J., Winn, R., Sugita, M., Tanaka, N., Ueki, M., & Drabkin, H. A.
- Venue
- British Journal of Cancer
- Published
- 2001-07
- Volume
- 85
- Issue
- 1
- Pages
- 64-68
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2005701750
- Cited by
- 132
- References
- 2
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.